Photo of Dr Marco Giardiello

Dr Marco Giardiello PhD, MChem, AFHEA

UKRI Research Fellow Chemistry


Inorganic/Organic Nanocomposite Particles (I/O-NP)

Inorganic nanoparticles are used in several diagnostic and therapeutic medical applications. There are multiple drawbacks, however, when inorganic nanoparticles are used in vivo, for example: non- specific targeting and physiological accumulation and associated toxicity risks; nanoparticle variation in properties due to protein binding/immune response. Research is aimed at addressing these issues through the development of Inorganic/Organic Nanocomposite Particles (I/O-NP), where the inorganic component is encapsulated within an organic framework. The platform technology allows for advantages such as: reduction in toxicity; inorganic nanoparticle protection from physiological processes; disease site specific targeting; high payload delivery.
Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields
Facile synthesis of complex multi-component organic and organic–magnetic inorganic nanocomposite particles

Solid Drug Nanoparticles (SDN)

As global populations grow and survival rates for numerous diseases increase, there is a significant rise in the need to address challenges in drug formulation and development while sustaining manufacturing capacity to meet demand. Many pharmaceuticals do not make it beyond pre-clinical studies into clinical use due to their low solubilities and/or poor bio availability. Research is towards the development of Solid Drug Nanoparticles (SDN), where the nanoparticle itself is composed entirely of the drug compound, stabilised by polymer/surfactant excipients. SDNs form colloidally stable aqueous dispersions of the drug, which show similar behaviour to molecularly dissolved solutions. Research has led to the cGMP development of antiretroviral SDNs for HIV therapy for the clinical manufacture and human testing of the first ever orally-dosed nanomedicine targeting HIV infection, with two in man clinical trials carried out (EudraCT number 2013-004913-41).
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies
Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation

Research Grants

Inorganic/Organic Nanocomposite Particles (I/O-NP); A Platform Technology for Next Generation Healthcare Applications


July 2020 - June 2024

New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery


July 2018 - June 2022

Increasing Industry Engagement and Open Innovation in Health and Life Sciences - Proximity to Discovery Award


March 2016 - August 2017